Association Between Anticholinergic Drug Use and Febrile Neutropenia Induced by Anticancer Chemotherapy: Analysis of the Japanese Adverse Drug Event Report Database.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-09-01 DOI:10.21873/invivo.14087

Anna Kato-Ogiso, Tomohiro Mizuno, Koki Kato, Fumihiro Mizokami, Sho Hasegawa, Tsuyoshi Nakai, Yosuke Ando, Masakazu Hatano, Takenao Koseki, Shigeki Yamada

{"title":"Association Between Anticholinergic Drug Use and Febrile Neutropenia Induced by Anticancer Chemotherapy: Analysis of the Japanese Adverse Drug Event Report Database.","authors":"Anna Kato-Ogiso, Tomohiro Mizuno, Koki Kato, Fumihiro Mizokami, Sho Hasegawa, Tsuyoshi Nakai, Yosuke Ando, Masakazu Hatano, Takenao Koseki, Shigeki Yamada","doi":"10.21873/invivo.14087","DOIUrl":null,"url":null,"abstract":"Background/aim: We previously reported that benzodiazepines with anticholinergic effects are a risk factor for infection in patients with diffuse large B-cell lymphoma; however, the effects of other anticholinergic drugs and the trend of severe infections, such as febrile neutropenia (FN), have not been investigated. The Japanese Anticholinergic Risk Scale (JARS) was developed by the Japanese Society of Geriatric Pharmacy to screen for potentially inappropriate medications with anticholinergic effects. This study aimed to elucidate the trend of FN induced by anticancer chemotherapy in patients who received anticholinergic drugs listed in the JARS.Patients and methods: We obtained data from the JADER. Reporting odds ratios (RORs) were used to detect safety signals for FN. Anticholinergic drugs were classified into three categories according to their JARS score. Safety signals for FN were considered positive if the lower limit of the 95% confidence interval (CI) of the ROR was >1.Results: A total of 162,918 cases were included in the dataset. RORs for FN indicated that cases with an anticholinergic risk score of 1 and 3 showed a safety signal (score 1: ROR=1.748, 95%CI=1.659-1.841; score 3: ROR=1.525, 95%CI=1.371-1.696), while no safety signals were observed for those with a risk score of 2 (ROR=1.015, 95%CI=0.863-1.194). Similar trends were observed in cases 70 years old and over and those under 70 years old.Conclusion: The trend of FN in patients who received an anticholinergic drug listed in the JARS was similar among younger and older patients.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2872-2882"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396082/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: We previously reported that benzodiazepines with anticholinergic effects are a risk factor for infection in patients with diffuse large B-cell lymphoma; however, the effects of other anticholinergic drugs and the trend of severe infections, such as febrile neutropenia (FN), have not been investigated. The Japanese Anticholinergic Risk Scale (JARS) was developed by the Japanese Society of Geriatric Pharmacy to screen for potentially inappropriate medications with anticholinergic effects. This study aimed to elucidate the trend of FN induced by anticancer chemotherapy in patients who received anticholinergic drugs listed in the JARS.

Patients and methods: We obtained data from the JADER. Reporting odds ratios (RORs) were used to detect safety signals for FN. Anticholinergic drugs were classified into three categories according to their JARS score. Safety signals for FN were considered positive if the lower limit of the 95% confidence interval (CI) of the ROR was >1.

Results: A total of 162,918 cases were included in the dataset. RORs for FN indicated that cases with an anticholinergic risk score of 1 and 3 showed a safety signal (score 1: ROR=1.748, 95%CI=1.659-1.841; score 3: ROR=1.525, 95%CI=1.371-1.696), while no safety signals were observed for those with a risk score of 2 (ROR=1.015, 95%CI=0.863-1.194). Similar trends were observed in cases 70 years old and over and those under 70 years old.

Conclusion: The trend of FN in patients who received an anticholinergic drug listed in the JARS was similar among younger and older patients.

Abstract Image

查看原文本刊更多论文

抗胆碱能药物的使用与抗癌化疗所致发热性中性粒细胞减少的关系：日本不良药物事件报告数据库的分析。

背景/目的：我们之前报道过具有抗胆碱能作用的苯二氮卓类药物是弥漫性大b细胞淋巴瘤患者感染的危险因素；然而，其他抗胆碱能药物的作用和严重感染的趋势，如发热性中性粒细胞减少症（FN），尚未调查。日本抗胆碱能风险量表（JARS）是由日本老年药学学会开发的，用于筛选具有抗胆碱能作用的潜在不适当药物。本研究旨在阐明在接受jar所列抗胆碱能药物治疗的患者中，抗癌化疗诱导FN的变化趋势。患者和方法：我们从JADER获得数据。报告优势比（RORs）用于检测FN的安全信号。抗胆碱能药物根据其jar评分分为三类。如果ROR的95%置信区间（CI）的下限为bb0.1，则认为FN的安全信号为阳性。结果：数据集中共纳入162918例病例。抗胆碱能风险评分为1和3分的患者存在安全信号（评分1:ROR=1.748, 95%CI=1.659-1.841；评分3:ROR=1.525, 95%CI=1.371-1.696），评分2的患者无安全信号（ROR=1.015, 95%CI=0.863-1.194）。在70岁以上和70岁以下的人群中也观察到类似的趋势。结论：老年和年轻患者在接受《临床胆碱能药物分类》所列抗胆碱能药物治疗时FN的变化趋势相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.